News | October 23, 2025
Ipsen to acquire ImCheck Therapeutics to strengthen oncology pipeline
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
This new facility strengthens Latin America as a collaborative hub
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
Sourced and formulated in the United States, Ameriflor Calm is derived from plants grown on regenerative organic certified farms and is manufactured at a site that uses 100% renewable electricity
Lutavit A/D3 1000/200 NXT provides a combination of vitamin A and vitamin D3 in one formulation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
